Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (5537)	1/24/2002 4:46:31 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Ariad I had the impression they were among the elite of the former group, publishing many articles per year (including, invariably, some in Science/Nature/Cell). And they unbelievably hyped their stock (up to nearly $50 if I recall) in early 2000, even though they were many years away from any practical application of their technology. Peter

To: scott_jiminez who wrote (5537)	1/24/2002 9:46:24 PM
From: hm	Read Replies (2) \| Respond to of 52153

>>One need not put up with 'public claims'; peer-reviewed disclosure is not the gold-standard. It's the only standard.<< It may be the only standard for an academic. And even that standard has many flaws as anybody who has been involved in the process knows. At the risk of stating the blatantly obvious, biotech & pharma exist at the business / science interface, a place far far away from academia. Manuscripts, abstracts, presentations are generally done to progress the interests of the company not out of some desire for academic glory. IMO, you have to judge any form data release in this context whether it's a NEJM article or a press release. Evaluating a compound in development by academic standards completely misses the point. On the other hand, as Peter pointed out, the FDA does get all the data. That's why the real moments of truth come from AC and FDA meetings not peer-reviewed publications. Finally, of course BT companies want investors to be interested in their company. Data release is an integral part of the process. Juicy data is released both to keep investors interested and to build demand for the new drug. Rant over hm